Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New online tool aims to sharpen thinking skills in teens with epilepsy

NCT ID NCT06608966

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a web-based program called Epilepsy Journey, which includes online modules and telehealth sessions with a therapist, to help teens with epilepsy improve their executive functioning skills like planning, organization, and emotional control. 310 teens aged 13-17 will be randomly assigned to different combinations of the program or usual care. The goal is to see which parts of the program are most effective at boosting thinking skills and quality of life over 66 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Epilepsy Journey web-based modules and telehealth sessions with a therapist
What this could lead to
If it works, this could provide a practical, non-drug way to help teens with epilepsy manage daily tasks and improve their quality of life.
What could go wrong
This is a behavioral intervention study, not a drug trial, so effects may be modest. The results depend on participant engagement and may not apply to all teens with epilepsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 310 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 13-17 years at the time of enrollment 2. Child lives at home with primary caregiver and is enrolled in school (excluding summer breaks). 3. Confirmed diagnosis of epilepsy with seizures that are categorized as either generalized or focal in onset. Epilepsy is defined as: 1) At least two unprovoked seizures occurring more than 24-hours apart; or 2) One unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures. 4. Primary language of English 5. Screening Inclusion: On the parent-reported Behavior Rating Inventory of Executive Function-2nd edition (BRIEF-2), have executive functioning deficits defined as at least 2 subclinical (60\<T\<65) or one clinical BRIEF-2 subscale T scores (T≥65). 6. Parent/legal guardian(s) willing to sign an IRB approved informed consent 7. Participant willing to sign an Institutional Review Board approved assent Exclusion Criteria: 1. Parent or clinician-reported history in the adolescent of: 1. developmental delay (e.g., autism spectrum disorder, pervasive development disorder, history of services for developmental delay or intellectual impairment in the past 5 years, known IQ\<70) 2. severe mental illness (e.g., schizophrenia, bipolar disorder, eating disorder within the past 12 months, depression with active suicidal ideation or suicidal ideation/intent in the past 3 months) 3. prior (3-months) or current history of trauma and/or stressor-related disorders (e.g. PTSD) 4. recent or current significant medical disease (i.e., cardiovascular, hepatic, renal, gynecologic, musculoskeletal, metabolic or endocrine) 5. brain injury or brain tumor; and/or 6. epilepsy surgery 7. any other medical and/or psychological condition that takes treatment precedence over the study intervention 2. Clinician-reported diagnosis in the adolescent of 1. epilepsy whose seizures are categorized only as either unknown onset or unclassified onset (defined as insufficient information to determine onset) 2. epilepsy currently being treated at the time of enrollment by 3 or more antiseizure medications (ASMs) (excluding rescue medication use) 3. epilepsy with a history of failure to achieve seizure freedom despite adequate use of 4 different anti-seizure medications 4. a confirmed or suspected epileptic encephalopathy (e.g., electrical status epilepticus in sleep, Landau Kleffner syndrome, West syndrome) 5. a confirmed or suspected progressive and degenerative disorder (e.g., mitochondrial disorders, metabolic disorders, autoimmune disorders) 6. one or more episodes of status epilepticus within the 24 weeks prior to enrollment; and/or 7. treatable causes of seizures, for example identified etiologies including metabolic, neoplastic, or active infectious origin. 8. non-epileptic event/seizures 3. Adolescents currently on the ketogenic diet 4. Participation in a trial of an investigational drug or device within 30 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy in children are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Childrens Hospital of Orange County

    RECRUITING

    Orange, California, 92868, United States

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.